Skip to content
About
Acer Management
Board of Directors
Key Strategic Consultants
Scientific Advisory Board
Careers
Pipeline
ACER-001 for UCDs
ACER-001 for MSUD
ACER-801 for iVMS
EDSIVO™ for vEDS
ACER-2820 for Infectious Diseases
Patients & Physicians
Patient Advocacy
Publications
Urea Cycle Disorders (UCDs)
Maple Syrup Urine Disease (MSUD)
Induced Vasomotor Symptoms (iVMS)
Vascular Ehlers-Danlos Syndrome (vEDS)
Infectious Diseases
Expanded Access
Investor Relations
Press Releases
Events & Presentations
SEC Filings
Analyst Coverage
Stock Information
Corporate Governance
Investor FAQs
Contact Us
About
Pipeline
Investor Relations
Publications
Contact Us
Investor FAQs
Analyst Coverage
Corporate Governance
Stock Information
Events & Presentations
About
Pipeline
Investor Relations
Publications
Contact Us
1
2
3
Developing therapies for patients
with serious,
rare and
life-threatening diseases
Acer is committed
to supporting patients
and families that
need it most.
Acer is
changing the path
to managing serious rare and
life-threatening diseases
QUICK
NAV
MENU
MENU
About
Acer Management
Board of Directors
Key Strategic Consultants
Scientific Advisory Board
Careers
Pipeline
ACER-001 for UCD
ACER-001 for MSUD
ACER-801 for iVMS
EDSIVO™ for vEDS
ACER-2820 for Infectious Diseases
Patients & Physicians
Patient Advocacy
Publications
Urea Cycle Disorders (UCDs)
Maple Syrup Urine Disease (MSUD)
Induced Vasomotor Symptoms (iVMS)
Vascular Ehlers-Danlos Syndrome (vEDS)
Infectious Diseases
Expanded Access
Investor Relations
Press Releases
Events & Presentations
SEC Filings
Analyst Coverage
Stock Information
Corporate Governance
Investor FAQs
Contact Us